| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 1424 |
| 1 | METHOTREXATE SODIUM | 1400 |
| 2 | ADALIMUMAB | 1299 |
| 3 | METHOTREXATE | 1239 |
| 4 | ETANERCEPT | 1152 |
| 5 | INFLIXIMAB | 1141 |
| 6 | PREDNISONE | 1124 |
| 7 | CYCLOPHOSPHAMIDE | 778 |
| 8 | CYCLOPHOSPHAMIDE FOR INJECTION | 778 |
| 9 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 778 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TAFASITAMAB-CXIX | 165 | 0.1821 |
| 1 | AMCINONIDE | 4 | 0.0471 |
| 2 | POLATUZUMAB VEDOTIN | 383 | 0.0375 |
| 3 | BENDAMUSTINE HCL | 373 | 0.0238 |
| 4 | SUTIMLIMAB-JOME | 7 | 0.0218 |
| 5 | GOLIMUMAB | 202 | 0.0160 |
| 6 | BERBERIS VULGARIS, ISATIS TINCTORIA, MORINDA CITRIFOLIA, PETIVERIA TETRANDRA, SCHINUS MOLLE, THYMOLUM, UVA-URSI | 4 | 0.0135 |
| 7 | INFLIXIMAB-DYYB | 41 | 0.0119 |
| 8 | IBRITUMOMAB TIUXETAN | 17 | 0.0112 |
| 9 | RALTEGRAVIR | 56 | 0.0107 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 2460 |
| 1 | Corticosteroid [EPC] | 2172 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 1542 |
| 3 | Folate Analog Metabolic Inhibitor [EPC] | 1242 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 997 |
| 5 | Alkylating Drug [EPC] | 875 |
| 6 | Thalidomide Analog [EPC] | 746 |
| 7 | Kinase Inhibitor [EPC] | 590 |
| 8 | Platinum-based Drug [EPC] | 447 |
| 9 | Vitamin C [EPC] | 442 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Human Platelet-derived Growth Factor [EPC] | 1 | 1.0000 |
| 1 | Interleukin-5 Antagonist [EPC] | 46 | 0.0669 |
| 2 | Classical Complement Pathway Inhibitor [EPC] | 7 | 0.0218 |
| 3 | Provitamin D2 Compound [EPC] | 295 | 0.0099 |
| 4 | Human Immunoglobulin G [EPC] | 159 | 0.0075 |
| 5 | CD19-directed Chimeric Antigen Receptor [EPC] | 67 | 0.0066 |
| 6 | CCR5 Co-receptor Antagonist [EPC] | 14 | 0.0061 |
| 7 | CD4-directed Blocking Antibody [EPC] | 3 | 0.0056 |
| 8 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 22 | 0.0054 |
| 9 | Interleukin-17A Antagonist [EPC] | 188 | 0.0050 |